-
1 Comment
Allakos Inc is currently in a long term downtrend where the price is trading 23.1% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Allakos Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 79.9% to $-44M since the same quarter in the previous year.
Finally, its free cash flow fell by 82.3% to $-35M since the same quarter in the previous year.
Based on the above factors, Allakos Inc gets an overall score of 1/5.
| Sector | Healthcare |
|---|---|
| Industry | Biotechnology |
| Exchange | NASDAQ |
| CurrencyCode | USD |
| ISIN | US01671P1003 |
| Market Cap | 30M |
|---|---|
| PE Ratio | None |
| Beta | 0.14 |
| Target Price | 0.3 |
| Dividend Yield | None |
As of May 15, 2025, operates as a subsidiary of Concentra Biosciences, LLC.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for ALLK using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
